福安藥業(300194.SZ):子公司左氧氟沙星注射液獲批上市
格隆匯5月9日丨福安藥業(300194.SZ)公佈,公司全資子公司福安藥業集團煙台只楚藥業有限公司(簡稱“只楚藥業”)於近日收到國家藥監局簽發的關於左氧氟沙星注射液的藥品註冊證書。
左氧氟沙星注射液用於治療成年人由敏感菌株所引起的下列感染:醫院獲得性肺炎、社區獲得性肺炎、急性細菌性鼻竇炎、慢性支氣管炎的急性細菌性發作、複雜性尿路感染等。
根據國家藥監局相關信息平台顯示:截止目前,左氧氟沙星注射液(含只楚藥業)共有3家企業通過一致性評價或視同通過一致性評價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.